Hematologic Oncology Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

CPMC offers the following hematologic oncology clinical trials:
 

Multiple Myeloma:

 

Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma

Description: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 y/o and older, who are diagnosed with symptomatic standard-risk multiple myeloma (SR-MM)

Status

Call site for study status

Contacts

Madeline Decker, 415-600-3613

 

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Description: This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 y/o and older, who are diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 60 months

Status

Call site for study status

Contacts

Madeline Decker, 415-600-3613

 

A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM). (KEYNOTE 183)

Description: The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free Survival (PFS) in participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, who have a confirmed diagnosis of active multiple myeloma and measurable disease and who have undergone prior treatment with ≥2 treatment lines of anti-myeloma therapy and must have failed last line of treatment (refractory to last line of treatment)

Status

Active and open to enrollment

Contacts

Madeline Decker, 415-600-3613

 

A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185)

Description: The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free survival (PFS) in participants with newly diagnosed and treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (Auto-SCT)

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, with a confirmed diagnosis of active multiple myeloma and measurable disease and who are ineligible to receive treatment with auto-SCT due to age, (≥65 years of age) or coexisting medical condition; participants <65 years of age who refuse auto-SCT are not eligible for this study

Status

Active and open to enrollment

Contacts

Madeline Decker, 415-600-3613

AML:

A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Description: The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine.
 

Investigators

  • Caroline Behler, MD
     

Eligibility Requirements

Subjects, 18 y/o and older, with newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))
 

Status

Active and open to enrollment
 

Contacts

Leslie Corona, 415-600-5766, Email: CoronaLA@cpmcri.org about Study SGN33A-005

Leukemia:

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Description: This study is to evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib

Investigators

  • Caroline Behler, MD

Eligibility Requirements

Subjects, 18 y/o and older, who have a diagnosis of elapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas

Status

Active and open to enrollment

Contacts

Madeline Decker, 415-600-3613